Success Metrics

Clinical Success Rate
78.7%

Based on 1,377 completed trials

Completion Rate
79%(1377/1750)
Active Trials
692(23%)
Results Posted
64%(881 trials)
Terminated
373(13%)

Phase Distribution

Ph phase_1
962
32%
Ph not_applicable
102
3%
Ph phase_4
42
1%
Ph phase_2
1,313
44%
Ph early_phase_1
47
2%
Ph phase_3
473
16%

Phase Distribution

1009

Early Stage

1313

Mid Stage

515

Late Stage

Phase Distribution2939 total trials
Early Phase 1First-in-human
47(1.6%)
Phase 1Safety & dosage
962(32.7%)
Phase 2Efficacy & side effects
1,313(44.7%)
Phase 3Large-scale testing
473(16.1%)
Phase 4Post-market surveillance
42(1.4%)
N/ANon-phased studies
102(3.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.3%

1377 of 1879 finished

Non-Completion Rate

26.7%

502 ended early

Currently Active

692

trials recruiting

Total Trials

2,972

all time

Status Distribution
Active(771)
Completed(1377)
Terminated(502)
Other(322)

Detailed Status

Completed1377
Recruiting411
Terminated373
unknown305
Active, not recruiting281
Withdrawn129

Development Timeline

Analytics

Development Status

Total Trials
2972
Active
692
Success Rate
78.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 147 (1.6%)
Phase 1962 (32.7%)
Phase 21313 (44.7%)
Phase 3473 (16.1%)
Phase 442 (1.4%)
N/A102 (3.5%)

Trials by Status

terminated37313%
completed137746%
active_not_recruiting2819%
suspended171%
not_yet_recruiting742%
recruiting41114%
withdrawn1294%
enrolling_by_invitation50%
unknown30510%

Recent Activity

Clinical Trials (2,972)

Showing 20 of 2,972 trialsScroll for more
NCT05645718Phase 2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting
NCT06500273Phase 2

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting
NCT05457556Phase 3

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Active Not Recruiting
NCT04994132Phase 3

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Active Not Recruiting
NCT07466316Phase 3

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT07572136Phase 1

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Not Yet Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT07524530Phase 2

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

Not Yet Recruiting
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT05600426Phase 3

A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Active Not Recruiting
NCT02654119Phase 2

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Completed
NCT05470283Phase 1

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active Not Recruiting
NCT05110742Phase 1

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Recruiting
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT00400946Phase 3

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Completed
NCT07735637Phase 3

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Not Yet Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT06904066Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Recruiting
NCT07072585Phase 2

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
2,972